ClinicalTrials.gg
CompletedNCT05098028Updated Sep 19, 2024Results posted

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

A Phase 2 interventional study of Low Dose Rifaximin ER and Low Dose Rifaximin DER in Sickle Cell Disease, sponsored by Bausch Health Americas, Inc.. Completed at 8 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
224th of 559
44 · median 31
Started
2022
with 40 others
Phase 2
161 of 733
23 open now
Registered
565th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 224th largest by enrollment of the 559 interventional ones that give a count, is one of 41 that started in 2022, is one of 161 in phase 2, and was the 565th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled study in sickle cell disease participants with a history of Vaso-occlusive Crises (VOCs). Approximately 60 participants with sickle cell disease will be enrolled and randomized: 12 participants in each of four active novel formulation rifaximin groups and 6 participants in each of 2 placebo groups.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ability and willingness to sign a written form.
  2. between the ages of 18 to 70 years old (inclusive) at the time of consent.
  3. SCD of any genotype (HbSS, HbSC, HbS β-thalassemia). If the subject's genotype has not been previously documented, genotyping will be performed during Screening using high-performance liquid chromatography (HPLC)/electrophoresis.
  4. least 2 VOCs within the 12 months prior to Screening.
  5. if receiving hydroxyurea (HU)/hydroxycarbamide (HC), subject must have been receiving the treatment for at least 6 months prior to Screening and must agree to maintain the same dose and schedule for the duration of the study.
  6. must have laboratory values at Screening as follows:

    1. ≥1.0 x 109/L
    2. ≥ 75 x 109/L
    3. (Hgb) ≥ 6.0 g/dL
    4. (GFR) ≥ 45 mL/min/1.73 m2 using the CKD-EPI formula
    5. Total ≤ 15 mg/dL
    6. (ALT) ≤ 3.0 x
    7. (INR) ≤ 2.0
  7. Eastern Cooperate Oncology Group () performance status ≤ 2
  8. Women of , defined as all women physiologically capable of becoming pregnant, must have a negative serum pregnancy test at Screening and agree to use standard prevention methods for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. receiving concomitant treatment with voxelotor, crizanlizumab, or L-glutamine.
  2. any history of stem cell transplant, is planning to begin or has received in past 30 days.
  3. acute VOC, requiring a visit to a medical facility and/or healthcare professional, ending within 7 days prior to Day 1 dosing.
  4. has received any blood products within 30 days prior to Day 1 dosing.
  5. uncontrolled liver disease or renal impairment, ulcerative colitis, Crohn's disease, or other chronic GI disorder.
  6. has received active treatment in another trial within 30 days or 5 half-lives of the last dose of the investigational agent, whichever is greater, prior to Screening.
  7. has received penicillin prophylaxis or antibiotics for treatment of infection within 30 days or 5 half-lives of the treatment, whichever is greater, prior to Screening.
  8. significant medical condition that required hospitalization (other than for a VOC) within 2 months prior to Screening.
  9. planning on undergoing an exchange transfusion during the duration of the study or has completed one within 4 weeks prior to Day 1 dosing.
  10. to rifaximin, rifampin, rifamycin antimicrobial agents, or any components of rifaximin ER and DER.
  11. pregnant or a nursing woman.
  12. history of illicit drug use or abuse, either documented or in the opinion of the Investigator.
  13. using any medication that is known to inhibit or induce , or P-gp and OATP1B1/B3 within 30 days or 5 half-lives, whichever is longer, prior to Day 1 dosing, or in the opinion of the Investigator, may affect the evaluation of the study product or place the subject at undue risk.
  14. has had any prior gastrointestinal surgery which has altered the anatomy of the esophagus, stomach, or small/large intestine (with the exception of appendectomy, cholecystectomy, and fundoplication).
  15. has had a colonoscopy or sigmoidoscopy within 30 days prior to Day 1 or plans to undergo such a procedure during the duration of the study.
  16. has used bowel prep, laxative, or enema within 30 days prior to Day 1.
  17. bleeding disorder including, but not limited to, acquired or congenital function defects, disseminated intravascular coagulation (DIC), bleeding factor deficiencies, hemophilia, idiopathic thrombocytopenia purpura (ITP), or von Willebrand's disease.
  18. planning to undergo a major surgical procedure during the duration of the study.
  19. positive test for (HIV)1 or HIV2.
  20. active infection (HBsAg positive). Prior infection that is not active (i.e., HBsAg negative, HBcAb positive, and HBsAb positive) is permitted.
  21. positive test for (HCV RNA). Prior infection with spontaneous resolution or sustained resolution for ≥ 24 weeks after cessation of antivirals is permitted.
  22. active COVID-19 infection or complication(s) related to COVID 19 infection that are unresolved or, in the opinion of the Investigator, may affect evaluation of the study drug or place the subject at undue risk.
  23. received a vaccine (including COVID-19 vaccine) within 2 weeks prior to Screening. If subject has received their first of two COVID-19 vaccination doses, as applicable, they must wait for at least 2 weeks after receiving the second dose, and be symptom-free, prior to beginning Screening. Subject must not be planning for COVID-19 or other vaccinations while on study.
  24. malignant disease. Exceptions include that were treated curatively and have not recurred within 2 years prior to study treatment, completely resected basal cell and squamous cell skin cancers, and any completely resected carcinoma in situ.
  25. prolonged as assessed by history within the past 3 months. For subjects with no historical ECG information, subject has a resting QTcF ≥ 460 msec for males and ≥ 470 msec for females at Screening.
  26. any unstable cardiac condition that, in the opinion of the Investigator, may worsen during the study or interfere with successful evaluation of the study treatment.
  27. serious mental or physical illness which, in the opinion of the Investigator, would compromise participation in the study.
  28. any condition which, in the opinion of the Investigator, is likely to interfere with the successful collection of the measurements required for the study.
  29. unable to understand or comply with study instructions and requirements.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Low Dose Rifaximin ER

    twice daily

    Drug: Low Dose Rifaximin ER

  • Experimental
    Low Dose Rifaximin DER

    twice daily

    Drug: Low Dose Rifaximin DER

  • Experimental
    High Dose Rifaximin ER

    twice daily

    Drug: High Dose Rifaximin ER

  • Experimental
    High Dose Rifaximin DER

    twice daily

    Drug: High Dose Rifaximin DER

  • Placebo comparator
    Placebo

    twice daily

    Drug: Placebo

Interventions

  • Low Dose Rifaximin Extended Release Twice Daily

  • DrugLow Dose Rifaximin DER

    Low Dose Rifaximin Delayed Extended Release Twice Daily

  • High Dose Rifaximin Extended Release Twice Daily

  • DrugHigh Dose Rifaximin DER

    High Dose Rifaximin Delayed Extended Release Twice Daily

  • DrugPlacebo

    Placebo Twice Daily

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration

    Maximum observed plasma concentration

    Time frame: Day 29

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneLow Dose Rifaximin ERHigh Dose Rifaximin ERLow Dose Rifaximin DERHigh Dose Rifaximin DERPlacebo
Started781199
Completed781198
Not completed00001

Outcome measures

PrimaryMaximum Plasma Concentration

Maximum observed plasma concentration

Time frame:
Day 29
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration
ng/mLLow Dose Rifaximin ERHigh Dose Rifaximin ERLow Dose Rifaximin DERHigh Dose Rifaximin DERPlacebo
Maximum Plasma Concentration0.5835 ± 86.30.7425 ± 58.40.2186 ± 124.00.7128 ± 50.1—

Adverse events

Collected over 28 days of treatment and 2 weeks of follow-up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose Rifaximin ER0/7 (0%)1/7 (14.3%)7/7 (100%)
High Dose Rifaximin ER0/8 (0%)0/8 (0%)8/8 (100%)
Low Dose Rifaximin DER0/11 (0%)2/11 (18.2%)9/11 (81.8%)
High Dose Rifaximin DER0/9 (0%)1/9 (11.1%)8/9 (88.9%)
Placebo0/9 (0%)0/9 (0%)5/9 (55.6%)
Most frequent serious events
Most frequent serious events
EventLow Dose Rifaximin ERHigh Dose Rifaximin ERLow Dose Rifaximin DERHigh Dose Rifaximin DERPlacebo
MalariaInfections and infestations1/70/81/111/90/9
PneumoniaInfections and infestations1/70/81/111/90/9
AnemiaBlood and lymphatic system disorders0/70/81/111/90/9
PyrexiaGeneral disorders0/70/80/111/90/9
SepsisInfections and infestations0/70/81/110/90/9
Abortion completePregnancy, puerperium and perinatal conditions0/70/81/110/90/9
Most frequent other events
Showing 10 of 75
Most frequent other events
EventLow Dose Rifaximin ERHigh Dose Rifaximin ERLow Dose Rifaximin DERHigh Dose Rifaximin DERPlacebo
Abdominal discomfortGastrointestinal disorders4/73/84/110/93/9
HeadacheNervous system disorders4/74/83/113/92/9
ArthralgiaMusculoskeletal and connective tissue disorders3/71/81/113/93/9
Pain in extremityMusculoskeletal and connective tissue disorders0/70/84/110/91/9
ThrombocytosisBlood and lymphatic system disorders2/72/80/110/90/9
Bacterial infectionInfections and infestations2/72/80/110/91/9
Platelet count increasedInvestigations2/70/80/110/90/9
C-reactive protein increasedInvestigations0/72/81/110/90/9
FatigueGeneral disorders0/71/81/111/92/9
Vessel puncture site painGeneral disorders0/70/80/110/92/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Low Dose Rifaximin ERHigh Dose Rifaximin ERLow Dose Rifaximin DERHigh Dose Rifaximin DERPlaceboTotal
Mean23.0 ± 3.7424.6 ± 4.1729.3 ± 10.5422.6 ± 4.1625.8 ± 5.9325.3 ± 6.85
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose Rifaximin ERHigh Dose Rifaximin ERLow Dose Rifaximin DERHigh Dose Rifaximin DERPlaceboTotal
Female5582323
Male2337621
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Low Dose Rifaximin ERHigh Dose Rifaximin ERLow Dose Rifaximin DERHigh Dose Rifaximin DERPlaceboTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American67107737
White101114
More than one race000000
Unknown or Not Reported010113
08

Study locations

8 sites
  • Bausch Site 105
    Orange, California 92868, United States
  • Bausch Site 103
    Denver, Colorado 80220, United States
  • Bausch Site 104
    Atlanta, Georgia 30329, United States
  • Bausch Site 101
    Syracuse, New York 13210, United States
  • Bausch Site 102
    Greenville, North Carolina 27834, United States
  • Bausch Site 201
    Montreal, Quebec H2X 3E4, Canada
  • Bausch Site 501
    Eldoret, 30100, Kenya
  • Bausch Site 502
    Kisumu, 40100, Kenya
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Sep 2023, 17 months.

Results were first posted in Sep 2024, 1 year after primary completion.

Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 17 months is below that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2021
First posted
Oct 28, 2021
StartActual
Mar 22, 2022
Primary completionActual
Sep 4, 2023
CompletionActual
Sep 4, 2023
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05098028
Responsible party
Sponsor
First posted
Oct 28, 2021
Start date
Mar 22, 2022
Primary completion
Sep 4, 2023
Completion
Sep 4, 2023
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Varsha Bhatt
study director · Bausch Health Americas, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion